Folate receptor alpha (FRα)

Assets acting on this target.

Class
FRα-directed antibody-drug conjugate
Pathway
antibody binds folate receptor alpha, overexpressed in ovarian and other epithelial tumors, delivering a cytotoxic payload; being tested head-to-head against the approved FRα ADC mirvetuximab soravtansine

Folate receptor alpha (FRα) is a cell-surface protein that binds folate (vitamin B9) and helps pull it into cells through a process called endocytosis, in which the cell membrane engulfs the receptor along with whatever is attached to it. Most normal adult tissues carry little FRα, but it is markedly overexpressed on several epithelial cancers, most notably ovarian and endometrial carcinomas and some lung adenocarcinomas. This combination of restricted normal-tissue expression and reliable internalization makes FRα an appealing target for antibody-drug conjugates (ADCs): a monoclonal antibody that recognizes FRα is chemically linked to a potent cytotoxic payload. When the antibody binds the receptor, the whole complex is drawn inside the tumor cell, where the payload is released and interferes with cell division or DNA integrity, killing the cancer cell while limiting exposure of healthy tissue. This targeted-delivery strategy aims to concentrate cytotoxic activity specifically in FRα-high tumors rather than relying on systemic chemotherapy alone. It is broadly relevant to ovarian cancer treatment, where high-grade epithelial tumors frequently display elevated folate receptor expression, and reflects a wider effort in oncology to use receptor-directed conjugates as more selective alternatives to conventional cytotoxic regimens.

By indication

Related mechanisms

Folate receptor alpha (FRα) drugs compared

5 drugs, stage by indication
5 drugs acting on Folate receptor alpha (FRα): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Rinatabart sesutecan (Rina-S)Genmabantibody-drug conjugatePhase 3Phase 3 in Endometrial Cancer; Phase 3 in Ovarian Cancer; Phase 2 in Non-Small Cell Lung Cancer; Phase 1/2 in HR+/HER2- Metastatic Breast Cancer
Sofetabart mipitecanEli Lillyantibody-drug conjugatePhase 3Phase 3 in Ovarian Cancer; Phase 1 in Non-Small Cell Lung Cancer
Torvutatug samrotecanAstraZenecaantibody-drug conjugatePhase 3Phase 3 in Ovarian Cancer
ABBV-901AbbVieundisclosedPhase 1Phase 1 in Ovarian Cancer
IMGN-151AbbVieantibody-drug conjugatePhase 1Phase 1 in Endometrial Cancer

← all mechanisms